A thoughtful guide to NAD+ care.How we review
Menu

Follow the sources.

Provider advertising, clinical research, and geographic records play different roles in this publication. These notes make the distinction visible. Sources checked September 18, 2026; current offers may change.

  1. FDA: questions and answers on dietary supplementsRegulatory categories and limits of premarket review.
  2. Martens et al. (2018): randomized oral NR crossover trialShort-term human biomarker and tolerability study; not a lifespan trial.
  3. Yoshino et al. (2021): NMN and muscle insulin sensitivitySmall randomized study in postmenopausal women with prediabetes; not evidence for NAD injections or general weight loss.
  4. OpenStax: energy in living systemsCoenzyme and redox chemistry, not treatment evidence.
  5. OpenStax: oxidative phosphorylationNADH and mitochondrial electron transport.
  6. PubChem: NAD chemical structure recordChemical identity; formula depends on the specified molecular form.
  7. NHS: understanding medical abbreviationsAbbreviations depend on clinical context; ask the author of a report to clarify.
  8. Trętowicz et al. (2026): whole-blood NAD and ageHuman study reporting no age-related whole-blood decline; does not measure every tissue.
  9. Human whole-blood NAD and aging (2022)Observational study with sex-related differences; not a dosing target.
  10. Dried blood spot measurement of NAD (2022)Analytical measurement research; assay validity is separate from clinical utility.
  11. Castro-Marrero et al. (2021): CoQ10 plus NADH in ME/CFSCombination trial in a specific diagnosed population; does not isolate NADH or establish NAD injection effects.
  12. CoQ10 plus NADH and exercise outcomes (2016)Randomized combination study in chronic fatigue syndrome.
  13. NR uptake and metastasis models (online 2022)Experimental cancer-model work; not a human cancer-risk estimate.
  14. Orr et al. (2023): NR in mild cognitive impairmentSmall randomized pilot of oral NR, distinct from NAD injections.
  15. Oral NR, cognition, and Alzheimer biomarkers (2025)Exploratory crossover study; not an established Alzheimer treatment.
  16. Phase II NR pilot in amnestic mild cognitive impairment (2026)Pilot trial; NAD biomarker increases did not establish improved principal cognitive outcomes.
  17. NR and cisplatin-induced neuropathy (2022)Preclinical research, not proof of nerve regeneration in consumers.
  18. Richie et al. (2015): oral glutathione randomized trialBody-store measurements; not a trial of combined NAD and glutathione injections.
  19. Comparative NAC and glutathione crossover study (2015)Oxidative-stress marker research; not proof of a NAD combination benefit.
  20. Dellinger et al. (2017): NR plus pterostilbene randomized trialCombination biomarker study with industry involvement; not a human longevity trial.
  21. Riche et al. (2014): pterostilbene metabolic-parameter trialA separate ingredient and population from an NR-only product.
  22. FDA: concerns with unapproved GLP-1 drugsQuality, identity, and dosing concerns; not a NAD combination efficacy study.
  23. FDA: compounding policies as GLP-1 supply stabilizesCurrent regulatory context; adding another ingredient does not create FDA approval.
  24. FDA: July 2026 compounding advisory committee materialsAgency evaluation includes MOTS-c-related substances and evidence gaps.
  25. FDA: frequently asked questions about animal drugsVeterinary drug categories and prescribing context.
  26. UC Davis: veterinary supplements and nutraceuticalsVeterinary supplement context; not a canine NAD efficacy trial.
  27. NCCIH: berberine and weight lossLimited oral evidence must not be transferred to patches.
  28. FDA: cosmetics labeling claimsDistinguishes appearance claims from drug claims.
  29. FDA: what you should know about eye dropsOphthalmic products require sterility; not evidence for NAD eye drops.
  30. Kind Patches: NAD+ product advertisingManufacturer claims, not independent clinical verification.
  31. UK ASA: Kind Patches ruling (2026)Advertising regulator found submitted evidence inadequate for the challenged claims; UK context, not an FDA action.
  32. Rho Nutrition: Liposomal NAD+Manufacturer label and billing terms; 100 mg NAD+ per 4 mL serving shown.
  33. Tru Niagen: 300 mg capsulesManufacturer label lists NR chloride; not direct NAD+.
  34. Life Extension: NAD+ Cell Regenerator and Resveratrol EliteManufacturer label and price snapshot; distinct from the plain NR formula.
  35. Life Extension: NAD+ Cell Regenerator 300 mgManufacturer product listing for the NR formula.
  36. Thorne: nicotinamide riboside ingredients and productsManufacturer describes NR hydrogen malate and related products.
  37. Cymbiotika: Liposomal NAD+Manufacturer describes a multi-ingredient packet; quality and benefit claims require separate evaluation.
  38. Quicksilver Scientific: NAD+ Gold 30 mLManufacturer describes NMN and refrigeration instructions despite the NAD product name.
  39. Renue By Science: NAD+ CompleteCurrent multi-ingredient label differs from some older listings; on-page starting prices vary.
  40. MitoQ: NAD+ Dual ActionManufacturer label contains niacinamide, NR, resveratrol, and PQQ.
  41. Qualia: NAD+ product pageManufacturer product and study claims; consult the current label and exact study design.
  42. Qualia: NAD+ ingredient discussionManufacturer explanation; not an independent comparison.
  43. Lumine Organics: NAD+ Renew product advertisingAdvertising uses NAD and NMN wording; exact active identity needs clarification.
  44. Aurevia Labs: NAD+ PerformanceOne of several similarly named sellers; identity must be matched to the actual order.
  45. Cata-Kor: NAD Core 250 mgManufacturer listing; confirm exact version and current label.
  46. Nutricost: NAD+ productManufacturer listing; separate from NMN and NAD-plus-resveratrol variants.
  47. Codeage: Liposomal NAD+ UltraManufacturer describes direct NAD plus several additional ingredients.
  48. Elysium: BasisManufacturer label for NR plus pterostilbene; claims and lot documentation are separate evidence.
  49. ProHealth: NAD Triple Boost with NMNManufacturer variant listing; do not assume all Triple Boost versions have identical formulas.
  50. Innerbody Labs: NAD+ SupportManufacturer page; related editorial content is not an independent comparison of its own product.
  51. Goli: Renew NAD+ gummiesManufacturer product advertising; format convenience is separate from efficacy.
  52. Force Factor: longevity collectionManufacturer lists multiple formats; match the exact product label.
  53. Eqqualberry: NAD+ Peptide Boosting SerumManufacturer cosmetic claims; does not isolate the effect of NAD.
  54. Numbuzin: No.9 NAD+ product setManufacturer product family; creams, toner, essence and patches differ.
  55. Medicube US: EGF NAD+ Firming SerumManufacturer cosmetic listing; not injectable or systemic-treatment evidence.
  56. Purito Seoul: product catalogOfficial catalog lists Retinol Retinal 2000 NAD+ Serum.
  57. Aramore: NAD topical and oral productsPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  58. JIYU: NAD moisturizing creamPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  59. BBB National Programs: Reus advertising decision, October 2025Primary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  60. NatureWise: official catalog, NAD+ Support ComplexPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  61. XKQ: NAD+ nicotinamide riboside listingPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  62. Selerb: Daily NAD+ for womenPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  63. Pure Health Max: NMN product explanationPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  64. Boostiva: product catalogPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  65. Happy Aging: NAD+ women longevity formulaPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  66. Tally Health: Super NADPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  67. Nature’s Fusions: Nutri Urolithin A diacetatePrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  68. Shed: NAD product discussionPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  69. The Vitamin Shoppe: NAD and NMN retail categoryPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  70. Qualia: manufacturer-reported controlled NAD studyPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  71. NYU: medical language processing abbreviation glossaryShows multiple clinical meanings for NAD; the author of a medical report should clarify the intended meaning.
  72. CoreAge Rx: current NAD+ offerProvider advertising; offer page displays $99/month. Checked September 18, 2026.
  73. CoreAge Rx: NAD+ Injectable product pageProvider advertising; product page displays a different starting price of $93/month.
  74. CoreAge Rx: NAD+ NasalProvider description of a different administration route.
  75. AgelessRx: NAD+ InjectionProvider product page. Customer surveys are not controlled clinical trials.
  76. AgelessRx: NAD+ offer and billing termsPromotional page contains multiple prices; verify selected plan and renewal.
  77. IVY RX: NAD+ InjectionProvider lists a starting price of $179/month and describes its testing process.
  78. Eden: NAD+ InjectionProvider advertises $91 for the first month; this is not a verified renewal price.
  79. Hone: Basic membership and medication costsProvider lists $165/month estimated NAD+ cost, $25/month membership, and a $25 onboarding fee. Optional consultation fees are separate.
  80. FDA: ingredients suitable for sterile compoundingSafety notice describing reported reactions and ingredient-quality concerns.
  81. FDA: compounding questions and answersExplains that compounded drugs are not FDA-approved.
  82. NIH Office of Dietary Supplements: niacinNutritional and biochemical context; not a clinical trial of NAD+ injections.
  83. Grant et al. (2019): NAD+ infusion metabolome pilotSmall human IV study; metabolic observations do not prove longevity or everyday benefits.
  84. Reyna et al. (2026): retrospective IV tolerability pilotRoute-specific retrospective tolerability evidence; not proof of effectiveness for home injections.
  85. FSMB: contact a state medical boardDirectory for checking clinician licensing with the relevant board.
  86. NABP: state boards of pharmacyDirectory for checking pharmacy credentials.
  87. US Census Bureau: 2025 Gazetteer filesPlace names, geographic identifiers, land areas and internal-point coordinates. Distances on this site are calculated straight-line estimates.
  88. Next Health: New York NAD+ therapyProvider advertises a New York City NAD+ service; inclusion is not independent clinical verification.